Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • Cancer vaccine win restores Wall Street’s faith in Moderna
  • Clinical Data

Cancer vaccine win restores Wall Street’s faith in Moderna

BioPharma Dive

Moderna gained $45 billion in market value in a single day, a surge that brought the company s stock to levels not seen since 2024 and saddled it with expectations that may be tough to meet.

Oncology

Read full story

pharminent August 20, 2026 (Last updated: August 21, 2026)

BioPharma Dive

Moderna gained $45 billion in market value in a single day, a surge that brought the company s stock to levels not seen since 2024 and saddled it with expectations that may be tough to meet.

Oncology

Read full story

Post navigation

Previous: Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa
Next: Regeneron’s Pasatru Wins Full FDA Approval for Ultra-Rare ‘Stone Man Disease’

Related Stories

  • Clinical Data

New Taiho, Cullian data heats up lung cancer drug battle

pharminent August 13, 2026
  • Clinical Data

Intellia finds genetic suspect for liver safety signals with ATTR gene therapy

pharminent August 7, 2026
  • Clinical Data

Parsortix study shows promise for ADC target detection

pharminent August 3, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.